THERAPY DOSSIER · th-51c80e13d15c

Reparixin

Drug · Interleukin-8 receptor A (CXCR1) and B (CXCR2) modulator (MODULATOR)

Evidence & regulatory context

Mechanism: Interleukin-8 receptor A (CXCR1) and B (CXCR2) modulator (MODULATOR)
Target: CHEMBL4029 (Interleukin-8 receptor A / CXCR1); CHEMBL2434 (Interleukin-8 receptor B / CXCR2)
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL191413 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: DF-1681Y; Repertaxin; Reparixina; Reparixine
Note: Not recorded

Clinical trials 10

2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00224406 ↗Injury indicationPHASE2completed

Repertaxin (reparixin) in prevention of primary graft dysfunction after lung transplantation

Ischemia-Reperfusion Injury · Lung Transplantation

Enrolment: 114 · Results not recorded

NCT00248040 ↗Injury indicationPHASE2completed

Two schedules of reparixin in prevention of delayed graft function after kidney transplant in high-risk patients

Ischemia-Reperfusion Injury · Kidney Diseases

Enrolment: 80 · Results not recorded

NCT01817959 ↗PHASE3completed

Reparixin in pancreatic islet transplantation

Islet Transplantation in Type 1 Diabetes Mellitus

Enrolment: 51 · Results not recorded

NCT04794803 ↗PHASE2/PHASE3terminated

Efficacy and safety of reparixin in hospitalised patients with COVID-19 pneumonia

Severe Pneumonia

Enrolment: 56 · Results not recorded

NCT01967888 ↗PHASE2/PHASE3completed

Reparixin in pancreatic islet auto-transplantation

Pancreatectomy for Chronic Pancreatitis

Enrolment: 104 · Results not recorded

NCT05835466 ↗PHASE2recruiting

Reparixin in patients with myelofibrosis (MPN-RC 120)

Myelofibrosis · Post-ET Myelofibrosis · Post-PV Myelofibrosis

Enrolment: 10 · Results not recorded

NCT02370238 ↗PHASE2completed

Paclitaxel in combination with reparixin vs paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (FRIDA)

Metastatic Breast Cancer

Enrolment: 194 · Results not recorded

NCT01861054 ↗PHASE2terminated

Safety and biological effects of orally administered reparixin in early breast cancer patients who are surgical candidates

Breast Cancer

Enrolment: 20 · Results not recorded

NCT01220856 ↗PHASE2completed

Reparixin following islet transplantation in patients with type 1 diabetes mellitus

Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus

Enrolment: 9 · Results not recorded

NCT02001974 ↗PHASE1completed

Reparixin in combination with weekly paclitaxel in HER2-negative metastatic breast cancer

Metastatic Breast Cancer

Enrolment: 33 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 20877331 ↗2010Reported benefit

Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury.

RatSpinal cord injuryUnspecifiedWistarFemale7.5 or 15 mg/kgAcute after injury

Model: Spinal cord injury at T4

Reparixin reduced acute inflammation, preserved gray matter, mildly improved motor function and reduced autonomic dysreflexia after SCI.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…